Page 2,642«..1020..2,6412,6422,6432,644..2,6502,660..»

Cryopreservation of induced pluripotent stem cells improved the most by one product

Posted: September 25, 2012 at 9:13 pm

Public release date: 25-Sep-2012 [ | E-mail | Share ]

Contact: David Eve cellmedicinect@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Tampa, Fla. (Sep. 25, 2012) In a study to determine the best cryopreservation (freezing) solution to maintain induced pluripotent stem (iPS) cells, a team of researchers from Japan compared 12 kinds of commercially prepared and readily available cryopreservation solutions and found that "Cell Banker 3" out-performed the other 11 solutions by allowing iPS cells to be preserved for a year at degrees C in an undifferentiated state.

The study is published in a recent special issue of Cell Medicine [3(1)], now freely available on-line at: http://www.ingentaconnect.com/content/cog/cm.

"iPS cells are a promising alternative to embryonic stem cells and can be used in place of bone marrow cells, stromal cells and adipose tissue-derived stem cells," said study co-author Hirofumi Noguchi, MD, PhD, Department of Gastroenterological Surgery, Transplant and Surgical Oncology at the Okayama University Graduate School of Medicine. "However, the viability of human iPS cells, like embryonic stem cells, decreases significantly during cryopreservation. A wide variety of cryopreservation solutions have been used, however many are toxic or ineffective for use in extended cryopreservation."

The researchers concluded that Cell Banker 3 showed the highest cell viability and proliferation of all the solutions examined and can be widely used as it does not require any special skills for use.

###

This research was among those studies presented at the 37th Annual Meeting of the Japan Society for Organ Preservation and Medical Biology (JSOPMB). Sixteen studies were published in this special issue of CELL MEDICINE. The theme of the issue is "Organ/Cell Transplantation and Regenerative Medicine."

Citation: Miyamoto, Y.; Noguchi, H.; Yukawa, H.; Oishi, K.; Matsushita, K.; Iwata, H.; Hayashi, S. Cryopreservation of Induced Pluripotent Stem Cells. Cell Med. 3(1):89-95; 2012.

Contact: Dr. Hirofumi Noguchi, Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata, Okayama 700-8558 Japan Tel + 81-86-235-7257; Fax + 81-86-221-8775 Noguchih2006@yahoo.co.jp / noguch-h@cc.okayama-u.ac.jp

Read this article:
Cryopreservation of induced pluripotent stem cells improved the most by one product

Posted in Stem Cells | Comments Off on Cryopreservation of induced pluripotent stem cells improved the most by one product

Isolating stem cells from brain tumors

Posted: September 25, 2012 at 9:13 pm

ScienceDaily (Sep. 25, 2012) A new video protocol in Journal of Visualized Experiments (JoVE) details an assay to identify brain tumor initiating stem cells from primary brain tumors. Through flow cytometry, scientists separate stem cells from the rest of the tumor, allowing quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.

"Overall, these tumors are extremely rare, with only around one in 100,000 people being diagnosed with a primary brain cancer," Dr. Sheila Singh, co-author and neurosurgeon from McMaster University, explains. "However, these tumors are the second most common malignancy in the pediatric population, and are behind only leukemia as the cancer with the highest mortality rate."

This publication is significant because it allows scientists to identify, purify, and study brain tumor initiating cells rapidly and without sample loss. Because these stem cells allow scientists to grow films in a petri dish, they serve as an effective model of a tumor expanding in the brain of a patient. Though not all tumors are actively driven by a stem cell, they do drive the most aggressively expanding tumors that lead to a negative prognosis. Typically, the median survival for patients with these types of tumors is fifteen-months, and they are almost uniformly fatal. Currently there is no prospect for a cure.

"Since 2003, we've been perfecting the technique to isolate stem cells from brain tumors," Dr. Singh explains. Stem cells have three key properties: self-renewal, multilineage differentiation, and longevity. Studying stem cells allow scientists to develop therapies that not only target the progenitor cells, but also many of the daughter cells. This is crucial because stem cells are often hard to eradicate without adverse effects to the rest of the body. Once daughter cells are identified, this procedure can be used to target and isolate these cells as well. Singh continues, "By describing the entire hierarchy of tumor progenitor cells, we can describe, characterize and target any point in the lineage. These techniques are going to help us characterize and isolate these cells to learn more about their molecular underpinnings and how to target them."

Given the small amount of tissue available to scientists like Dr. Singh, analytic procedures must be incredibly efficient and precise so as not to waste the precious material. Since Dr. Singh first identified brain tumor initiating cells, she has "recognized the difficulties in working with these tissues." Singh's lab "has focused on optimizing these procedures, which are limited by small cell numbers, to increase the data output." As such, JoVE's unique video-text hybrid serves as an effective means to transmit the procedures to Dr. Singh's colleagues and other cancer researchers. JoVE is the world's first peer-reviewed science video journal indexed in PubMed and MEDLINE.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by The Journal of Visualized Experiments.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Read more from the original source:
Isolating stem cells from brain tumors

Posted in Stem Cells | Comments Off on Isolating stem cells from brain tumors

Mouse pancreatic stem cells successfully differentiate into insulin producing cells

Posted: September 25, 2012 at 9:13 pm

Public release date: 25-Sep-2012 [ | E-mail | Share ]

Contact: David Eve cellmedicinect@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Tampa, Fla. (Sep. 25, 2012) In a study to investigate how transplanted islet cells can differentiate and mature into insulin-producing pancreatic cells, a team of Japanese researchers found that using a specific set of transcription factors (proteins that bind to specific DNA sequences) could be transduced into mouse pancreatic stem cells (mPSCs) using Sendai virus (SeV), a mouse influenza virus, as a carrier, or vector. The study is published in a recent issue of Cell Medicine [3(1)], now freely available on-line at: http://www.ingentaconnect.com/content/cog/cm.

"Diabetes is one of the most serious and prevalent metabolic diseases," said study co-author Dr. Hiroshi Yukawa, Department of Advanced Medicine in Biotechnology and Robotics, Nagoya University Graduate School of Medicine. "Islet cell transplantation has proven effective, however this strategy requires sufficient organ donors."

Given the shortage of donors, the researchers investigated factors that could impact on the expansion and differentiation of pancreatic stem cells (PSCs) into insulin-producing cells using combinations of varieties of transcription factors and the SeV mouse virus to carry the cells, thus increasing the number of functional islet cells available for transplantation.

SeV vectors, said the researchers, are superior to conventional virus vectors because "they do not go through a DNA phase" and can introduce foreign genes without toxicity into a variety of cell types.

The combination of transcription factors that produced the greatest impact on the differentiation of PSCs into insulin cells was Pdx-1 (Pancreatic and duodenal homeobox 1), NeuroD (neurogenic differentiation) and MafA (musculoaponeurotic fibrosarcoma oncogene A). "Our data suggest that the transduction of transcription factors using SeV vectors facilitates mPSCs differentiation into insulin producing cells and showed the possibility of regenerating B-cells by using transduced PSCs," concluded the researchers.

###

This research was among those studies presented at the 37th Annual Meeting of the Japan Society for Organ Preservation and Medical Biology (JSOPMB). Sixteen studies were published in this special issue of CELL MEDICINE. The theme of the issue is "Organ/Cell Transplantation and Regenerative Medicine."

Citation. Yukawa, H.; Noguchi, H.; Oishi, K.; Miyamoto, Y.; Inoue, M.; Hasegawa, M.; Hayashi, S. Differentiation of Mouse Pancreatic Stem Cells into Insulin-Producing Cells by Recombinant Sendai Virus-Mediated Gene Transfer Technology Cell Med. 3(1):51-61; 2012.

See the rest here:
Mouse pancreatic stem cells successfully differentiate into insulin producing cells

Posted in Stem Cells | Comments Off on Mouse pancreatic stem cells successfully differentiate into insulin producing cells

Pacemaker from Stem Cells Receives Research Funding

Posted: September 25, 2012 at 9:12 pm

(SACRAMENTO, Calif.) - Deborah K. Lieu, a stem cell scientist in cardiovascular medicine at UC Davis Health System, has received a $1.3 million research grant from the California Institute for Regenerative Medicine (CIRM) to develop stem cells that could serve as a biological alternative to the electronic pacemakers that people now use to regulate heart rhythm.

According to Lieu, each year 350,000 cardiology patients with abnormal heart rhythms receive electronic pacemakers to maintain a normal heart beat. The devices, while effective, have several disadvantages, including limited battery life and poor response to changing heart rates, such as when a person is exercising. Lieu, who is working with colleague Nipavan Chiamvimonvat, the Roger Tatarian Endowed Professor of Cardiovascular Medicine at UC Davis, plans to examine ways to improve the generation of pacemaking cells using human-induced pluripotent stem cells (hiPSCs), potentially creating what she calls a "biopacemaker."

"There are more than 3 million patients around the country who are dependent on electronic pacemakers," said Lieu. "Each one costs about $58,000 to implant and requires follow-up surgery about every 5 to 10 years to change batteries. Creating a biopacemaker from stem cells would avoid the burden of battery replacement and provide the physiological benefit of enabling a person's heart to naturally adapt to a rising heart rate during activities such as exercise."

Lieu's grant was among more than two dozen projects that received support from state stem cell agency's governing board last week as part of CIRM's Basic Biology awards program. The funding focuses on basic research projects that can provide a better understanding about the fundamental mechanisms of stem cell biology and move researchers closer to knowing how best to use stem cells to help patients.

To create the pacemaking cells, Lieu and her colleagues plan to manipulate an ion channel (the SK channels in cardiac myocytes) to alter the calcium signaling mechanisms during hiPSC differentiation. Stem cell scientists create hiPSCs - typically from an adult cell such as a skin cell - by inducing a "forced" expression of specific genes. Once reprogrammed, the cells take on a variety of capabilities (becoming pluripotent) and offer a range of stem cell treatment possibilities.

Development of a biopacemaker could also benefit the one-in-20,000 infants and premature babies suffering from congenital heart-rhythm dysfunction who currently are not suitable candidates for electronic pacemakers. Infants are physically too small for the device. A biological pacemaker could fit with their small stature and then grow as the infant grows.

Collaborating with Lieu and Chiamvimonvat on the research project will be Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Donald Bers, chair of the UC Davis Department of Pharmacology; and James Chan, assistant professor in the Department of Pathology and affiliated with the NSF Center for Biophotonics Science and Technology at UC Davis.

UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university's hub for stem cell science. It includes Northern California's largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university's Clinical and Translational Science Center, and focus on turning stem cells into cures. For more information, visit http://www.ucdmc.ucdavis.edu/stemcellresearch.

Read more from the original source:
Pacemaker from Stem Cells Receives Research Funding

Posted in Cell Medicine | Comments Off on Pacemaker from Stem Cells Receives Research Funding

Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant …

Posted: September 25, 2012 at 1:11 pm

CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS (brentuximab vedotin) for post-transplant Hodgkin lymphoma (HL) patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

We are pleased to complete the enrollment of this important phase III trial, evaluating the use of ADCETRIS for Hodgkin lymphoma patients who are at high risk of residual disease following an ASCT, said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. The AETHERA trial is designed to provide the medical community with valuable insight into the potential for ADCETRIS to consolidate responses in Hodgkin lymphoma patients following a transplant, and will be the first data on the use of ADCETRIS in a maintenance-type setting. We anticipate data from this trial will be available in late 2013 or early 2014.

Completing enrollment of the AETHERA trial in the post-transplant Hodgkin lymphoma patient population at high risk for residual disease is a significant milestone for our ADCETRIS clinical development program, said Karen Ferrante, M.D., Chief Medical Officer, Millennium. We look forward to continuing to work with our partner Seattle Genetics to determine the potential benefit of this targeted treatment in other CD30-expressing tumors.

The AETHERA trial is a randomized, double-blind, placebo-controlled phase III study, comparing progression-free survival in 329 post-ASCT patients receiving ADCETRIS to those receiving placebo. Patients must be at high risk for residual HL, defined as those with a history of refractory HL, those who relapse or progress within one year from receiving front-line chemotherapy and/or those who have disease outside of the lymph nodes at the time of pre-ASCT relapse. Secondary endpoints of the trial include overall survival, safety and tolerability. Patients receive ADCETRIS every three weeks for up to approximately one year. This international multi-center trial is being conducted in the United States, Europe and Russia.

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS.

ADCETRIS is not approved for use outside the United States. The marketing authorization application for ADCETRIS in relapsed or refractory Hodgkin lymphoma and sALCL, filed by Takeda Global Research & Development Centre (Europe), was accepted for review by the European Medicines Agency (EMA) in June 2011. In July 2012, the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion for the conditional approval of ADCETRIS, supporting an approval decision in the European Union.

Seattle Genetics and Millennium are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.

View original post here:
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant ...

Posted in Genetics | Comments Off on Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant …

Therapeutic impact of cell transplantation aided by magnetic factor

Posted: September 25, 2012 at 8:10 am

Public release date: 24-Sep-2012 [ | E-mail | Share ]

Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Sept. 24, 2012) Two studies in the current issue of Cell Transplantation (21:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, demonstrate how the use of magnetic particles are a factor that can positively impact on the targeted delivery of transplanted stem cells and to also provide better cell retention.

A research team from the University of British Columbia used focused magnetic stem cell targeting to improve the delivery and transport of mensenchymal stem cells to the retinas of test rats while researchers from Cedars-Sinai Heart Institute (Los Angeles) injected magnetically enhanced cardiac stem cells to guide the cells to their target to increase cell retention and therapeutic benefit in rat models of ischemic/reperfusion injury.

According to study co-author Dr. Kevin Gregory-Evans, MD, PhD, of the Centre for Macular Degeneration at the University of British Columbia, degeneration of the retina - the cause of macular degeneration as well as other eye diseases - accounts for most cases of blindness in the developed world. To date, the transplantation of mensenchymal stem cells to the damaged retina has had "limited success" because the cells reaching the retina have been in "very low numbers and in random distribution."

Seeking to improve stem cell transplantation to the retina, the researchers magnetized rat mesenchymal stem cells (MSCs) using superparamagnetic iron oxide nanoparticles (SPIONs). Via an externally placed magnet, they directed the SPION enhanced cells to the peripheral retinas of the test animals.

"Our results showed that large numbers of blood-borne magnetic MSCs can be targeted to specific retinal locations and produce therapeutically useful biochemical changes in the target tissue," explained Gregory-Evans. "Such an approach would be optimal in focal tissue diseases of the outer retina, such as age-related macular degeneration."

Contact:

Dr. Kevin Gregory-Evans, Centre for Macular Research, Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow St., Vancouver, BC, Canada, V5Z 3N9 Tel. + 1-604-671-0419 Fax. + 1-604-875-4663 Email: kge30@interchange.unc.ca

Citation: Yanai, A.; Hfeli, U. O.; Metcalfe, A. L.; Soema, P.; Addo, L.; Gregory-Evans, C. Y.; Po, K.; Shan, X.; Moritz, O. L.; Gregory-Evans, K. Focused Magnetic Stem Cell Targeting to the Retina Using Superparamagnetic Iron Oxide Nanoparticles. Cell Transplant. 21(6):1137-1148; 2012.

Continue reading here:
Therapeutic impact of cell transplantation aided by magnetic factor

Posted in Stem Cell Videos | Comments Off on Therapeutic impact of cell transplantation aided by magnetic factor

How stem cells can heal

Posted: September 25, 2012 at 8:10 am

Part II

Stem cells are part of the new age of medicine. Even if it had its beginnings centuries ago, today, because of advanced technology, its full potential can be powerfully and easily harnessed.

What is the intrinsic nature of a stem cell? There are three types:

But this again is like going through the history of stem cells. This was the general thinking then.

But now, medicine is changing in the way it views life. Why? Because recent studies have since shown strong evidence of something amazing.

Adult stem cells (ASC) were once generally considered multipotent. But today, there is reason to believe that adult stem cells have pluripotent and totipotent capabilities.

Therefore, is science expanding in knowledge, or is this proof that our bodies are evolving, adapting, surviving and even surpassing our own limitations?

The breaking news is this: adult stem cells were identified that appear even more primitive or pluripotent than embryonic stem cells. Translation: A persons very own stem cells can be harvested, stored and reintroduced into the body in strategic organs or tissues via injection.

Another approach is to support the release of stem cells from the bone marrow. The use of adult stem cells transcends and bypasses all ethical boundaries facing embryonic stem cell research and approaches.

Stemness

See more here:
How stem cells can heal

Posted in Stem Cell Videos | Comments Off on How stem cells can heal

Stem cells revolutionizing veterinary medicine

Posted: September 25, 2012 at 8:10 am

(WGBA/NBC) - It is a story that gives hope to pet owners all over the country stem cell therapy for animals suffering from problems like arthritis or hip displaysia.

Stem cells are taken out of the dog's fatty tissue are harvested then injected into problem areas leaving the dogs completely healed.

"We couldn't take him on walks, he just laid around a lot," said Keith Nosowiak, Deniro's owner.

"We'd hear whimpering overnight, she'd take a few steps and she would sit down," said Luther Kortbein, Shadow's owner.

Until two months ago, Deniro suffered from severe arthritis, Shadow from hip displaysia.

Deniro's owner thought he may even have to put his German shepherd down.

"We felt we had a decision to make with his quality of life and being in pain we didn't want him to be in pain," Noskowiak said.

Shadow's owner was willing to try anything to cure her.

"Whatever the cost needed to get this done we were willing to do," Kortbein said.

Then Packerland Veterinary Center offered them stem cell therapy by using the dogs own stem cells and then injecting them back into the bloodstream joints.

See more here:
Stem cells revolutionizing veterinary medicine

Posted in Stem Cell Videos | Comments Off on Stem cells revolutionizing veterinary medicine

Cancer Stem Cells Drug Pipeline Update 2012

Posted: September 25, 2012 at 8:10 am

NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Stem Cells Drug Pipeline Update 2012

http://www.reportlinker.com/p0980850/Cancer-Stem-Cells-Drug-Pipeline-Update-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells.

There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

Originally posted here:
Cancer Stem Cells Drug Pipeline Update 2012

Posted in Stem Cell Videos | Comments Off on Cancer Stem Cells Drug Pipeline Update 2012

BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

Posted: September 25, 2012 at 6:15 am

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces Therapeutic Workshops on Cancer stem cell therapy, kinase drugs, and ultra rare diseases planned for the upcoming BIO Investor Forum. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

This years Therapeutic Workshops will address some of the most exciting therapeutic advances for the biotech industry. We have worked very closely with this years esteemed Advisory Committee to identify topics that will engage investors and industry alike, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

Therapeutic Workshops will feature senior-level industry executives, scientific officers and leading clinical experts that represent innovative investment opportunities in the biotech industry.

Therapeutic Workshops include:

The BIO Investor Forum features public and venture-stage company presentations, expert-led, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Advance media registration is available here. Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

View original post here:
BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

Posted in Biotechnology | Comments Off on BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

Page 2,642«..1020..2,6412,6422,6432,644..2,6502,660..»